Wells Fargo Maintains Overweight on Nurix Therapeutics, Lowers Price Target to $28

Wells Fargo analyst Derek Archila maintains Nurix Therapeutics (NASDAQ:NRIX) with a Overweight and lowers the price target from $29 to $28.